Revitalizing embolic protection in saphenous vein grafts

Catheterization and Cardiovascular Interventions

Volumn 76, Issue 2, 2010, Pages 270-271

  Satler, Lowell F ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PROTECTIVE AGENT;

ARTIFICIAL EMBOLISM; BLOOD VESSEL GRAFT; DEVICE; DRUG ELUTING STENT; EDITORIAL; FILTER; HEART CATHETERIZATION; HUMAN; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; RISK ASSESSMENT; SAPHENOUS VEIN GRAFT; SURGICAL TECHNIQUE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; DRUG-ELUTING STENTS; EMBOLISM; GRAFT OCCLUSION, VASCULAR; HUMANS; METALS; PRACTICE GUIDELINES AS TOPIC; PROSTHESIS DESIGN; SAPHENOUS VEIN; STENTS; TREATMENT OUTCOME;

EID: 77955150805     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22708     Document Type: Editorial

References (6)

1. Badhey N, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Addo TA, Haagen D, Abdel-karim A-R, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S, Brilakis ES. Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the SOS (Stenting Of Saphenous vein grafts) Trial. Catheter Cardiovasc Interv 2010.
2. Mauri L, Cox D, Hermiller J, Massaro J, Wahr J, Tay SW, Jonas M, Popma JJ, Pavliska J, Wahr D, Rogers C. The PROXIMAL trial: Proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: A randomized, prospective, multicenter clinical trial. J Am Coll Cardiol 2007;50:1442-1449. (Pubitemid 47494591)
3. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neil WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166-e286.
4. Hong YJ, Pichard AD, Mintz GS, Kim SW, Lee SY, Kim SY, Ahn Y, Jeong MH, Satler LF, Kent KM, Suddath WO, Weissman NJ, Kang JC, Waksman R. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. Am J Cardiol 2010;105:179-185.
5. Fischell TA, Subraya RG, Ashraf K, Perry B, Haller S. "Pharmacologic" distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention. J Invasive Cardiol 2007;19:58-62.
6. Giugliano GR, Kuntz RE, Popma JJ, Cutlip DE, Baim DS. Saphenous Vein Graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol 2005;95:173-177.